Initiatives to Promote the Discovery of Drugs to Improve Cognitive Function in Severe Mental Illness
J Clin Psychiatry 2006;67(7):e03
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Current pharmacotherapy for treating schizophrenia is
limited because treatments focus on positive symptom control rather than
improving social and vocational function and few new treatments have been
developed in the past 50 years. To better facilitate the development of
treatments for the cognitive impairments in schizophrenia and for improving
functional outcome in schizophrenia, the Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) program was established. The
MATRICS program has developed a way of measuring outcome in trials of
cognition-enhancing drugs, provided guidelines for doing studies of
cognition-enhancing drugs, and looked
at the most promising molecular targets for improving cognition using different
kinds of pharmacologic agents. By focusing on cognitive impairments and negative
symptoms, the functional outcomes of patients with schizophrenia may be
This expired activity is not currently available online. Please send us an email to request it. Activities with user requests will receive priority as we make more expired activities available.